Weakness in Loncar Cancer Immunotherapy ETF's Process and People Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative. The portfolio maintains a cost advantage over competitors, priced within the second-cheapest fee quintile among peers.  

 The strategy receives a Low Process Pillar rating. Independent of the rating, analysis of the strategy's portfolio shows it has maintained an overweight in liquidity exposure and an underweight in quality exposure compared with category peers. High liquidity exposure is attributed to stocks with a high trading volume, lending managers more flexibility. And a low quality exposure is rooted in stocks with higher financial leverage and lower profitability. The team managing this passive strategy earns a Low People Pillar rating. The strategy's parent organization still has a way to go to reach the industry standard, evidenced by a lack of inside investments from portfolio managers and a relatively inexperienced portfolio management team. As a result, the firm obtains a Below Average Parent Pillar rating.

Analyst Rating

Geron

Acrivon Therapeutics Inc

Enliven Therapeutics Inc

Janux Therapeutics

Nuvation Bio

Day One Biopharmaceuticals

2Seventy Bio

Revolution Medicines

ImmunityBio

Lyell Immunopharma

Morningstar's evaluation of this security's process aims to determine the likelihood that it will outperform its Morningstar Category benchmark on a risk-adjusted basis over the long term. Loncar Cancer Immunotherapy ETF earns a Low Process Pillar rating. The predominant detractor from the rating is the fund's unremarkable long-term risk-adjusted performance. This can be seen in its five-year alpha calculated relative to the category index, which suggests that the process has struggled over that period. The parent firm's five-year risk-adjusted success ratio of 0% also limits the process. The measure indicates the percentage of a firm's funds that survived and beat their respective category's median Morningstar Risk-Adjusted Return for the period. The parent's subpar success ratio suggests that the firm could do better across its fund lineup. The parent firm's five-year retention rate of 50% detracts from the rating further.

The investment strategy as stated in the fund's prospectus is:  The investment seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index (the “index”).  The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, and at least 80% of the fund’s total assets will be invested in the component securities of the index. 

 The portfolio has allocations in its top two sectors, healthcare and financial services, that are similar to the category. The sectors with low exposure compared to category peers are basic materials and technology; however, the allocations are similar to the category. The portfolio is composed of 81 holdings and is diversified among those holdings. In its most recent portfolio, 27.7% of the portfolio's assets were concentrated in the top 10 fund holdings, as opposed to the category average's 38.7%. And finally, in terms of portfolio turnover, looking at year-over-year movements, 86% of the fund's holdings have changed, whether through increasing, decreasing, or changing a position.

Process

Loncar’s team earns a Low People Pillar rating. The number one detractor from the rating is the experience of the management team, which averages four years at this fund. The instability of management across its parent firm also weakens the team. The firm's asset-weighted manager tenure of less than a year suggests it could do more to retain portfolio managers. The parent firm's five-year success ratio of 0% further holds the rating back. The measure indicates the percentage of a firm's funds that survived and beat their respective category's median return for the period. The parent's subpar success ratio suggests that the firm could do better across its fund lineup.

People

In an increasingly competitive industry, Loncar falls behind on a number of key metrics, resulting in a Below Average Parent Pillar rating. A quality holding back Loncar from the top tier of stewards is its managers' limited personal investments in their respective products, which helps to align portfolio manager and shareholder interests. Currently, none of the firm’s assets are covered by invested managers. A cause for concern at Loncar is its relatively inexperienced longest-tenured management. In particular, average asset-weighted tenure at the firm is only one year, a negative contributor to the rating.

Below Average

Parent

Loncar Cancer Immunotherapy ETF

CNCR tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.

CNCR tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products.

First Trust SkyBridge Crypto Industry and Digital Economy ETF

Invesco KBW Property & Casualty Insurance ETF

VanEck Vectors Semiconductor ETF

Roundhill Cannabis ETF

Wall Street is set to wrap up the first quarter with strong gains. The gains were broad-based and well spread out across various segments.

5 Market-Beating Sector ETFs of Q1

Virtus LifeSci Biotech Clinical Trials ETF

Breakwave Dry Bulk Shipping ETF

Simplify Tail Risk Strategy ETF

Proshares Ether Strategy Etf

Amplify Junior Silver Miners ETF

United States Natural Gas Fund LP

Sprott Junior Uranium Miners ETF

Invesco DB US Dollar Index Bullish Fund

Themes Generative Artificial Intelligence ETF

Wall Street surged to close out February with the S&P 500 and Nasdaq Composite notching their best February since 2015.

Top & Flop ETF Areas of Wall Street's Best February in Decade

First Trust RBA American Industrial Renaissance ETF

Invesco Dynamic Building & Construction ETF

The gains were broad-based and well spread out across various segments. We have highlighted some of the top performers in the ETF space from different sectors of the market.

5 Best-Performing Sector ETFs of February

MicroSectors FANG+ ETN

A combination of factors, including a solid earnings season, a resilient economy and a technology surge, powered the rally, resulting in a gain of about 5% for the S&P 500 Index this year.

5 Sector ETFs Beating the Market Halfway Through Q1

Range Global Coal Index ETF

Range Global LNG Ecosystem Index ETF

Range Nuclear Renaissance Index ETF

Range Global Offshore Oil Services Index ETF

Range ETFs expanded its lineup on Wednesday to include four energy-related ETFs. They cover the coal, natural gas, oil services, and nuclear industries.

Range Debuts 4 Energy-Related ETFs

Global X Artificial Intelligence & Technology ETF

Amplify Lithium & Battery Technology ETF

Global X Cybersecurity ETF

Bitwise Web3 ETF

Roundhill Generative AI & Technology ETF

First Trust NASDAQ Cybersecurity ETF

VanEck Video Gaming and eSports ETF

Amplify Cybersecurity ETF

iShares Genomics Immunology and Healthcare ETF

iShares Cybersecurity and Tech ETF

Global X Lithium & Battery Tech ETF

TrueShares Technology, AI and Deep Learning ETF

Roundhill Ball Metaverse ETF

MUSQ Global Music Industry ETF

Defiance Quantum ETF

ALPS Medical Breakthroughs ETF

Robo Global Artificial Intelligence ETF

SoFi Web 3 ETF

WisdomTree Cybersecurity Fund

Wisdomtree Artificial Intelligence And Innovation Fund

To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.

Disruptive Tech Theme of the Week: 7 Disruptive Themes for 2024

ARK Genomic Revolution Multi-Sector ETF

iShares MSCI Israel ETF

VanEck Vectors Israel ETF

Subversive Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Invesco WilderHill Clean Energy ETF

Invesco Solar ETF

Strategic Crispr & Gene Editing Technology ETF

After a downbeat September, October too remained volatile for Wall Street due to higher rates.

5 ETF Areas That Spooked Investors in October

Loncar China Biopharma ETF

Parabla Innovation Etf

Advocate Rising Rate Hedge ETF

SPDR S&P 500 ETF Trust

AXS Brendan Wood TopGun Index ETF

Kurv Yield Premium Strategy Apple AAPL Etf

FT Cboe Vest Laddered Moderate Buffer ETF

Simplify Developed EX-US Plus Downside Convexity

Simplify Emerging Markets Equity Plus Downside Convexity ETF

First Trust MLP & Energy Income Fund

First Trust Energy Income and Growth Fund

First Trust Energy Infrastructure Fund

First Trust New Opportunities Mlp & Energy Fund

Kurv Yield Premium Strategy Netflix NFLX ETF

Rayliant Quantamental Emerging Market Equity ETF

Kurv Yield Premium Strategy Tesla TSLA ETF

Xtrackers USD High Yield BB-B ex Financials ETF

FT Cboe Vest US Equity Moderate Buffer ETF - October

FT Cboe Vest US Equity Enhance & Moderate Buffer ETF - October

While the ETF industry didn't see over-the-top activity, the past week was fairly busy, with 11 new ETFs making their debut and six ETFs shutting down. Among the launches were two covered call funds from Goldman Sachs and a new fund from YieldMax that offers a covered call strategy tied to the stock of Moderna.

This Week in ETFs: 4 New Single-Stock Funds Debut

OKLAHOMA CITY , Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC, adviser to the Range Cancer Therapeutics ETF (CNCR) and the Loncar China BioPharma ETF (CHNA) is pleased to announce the completion of the reorganization of CHNA into CNCR following the close of business on October 20, 2023. When the Nasdaq Stock Market opens on Monday, October 23, 2023, shareholders of CHNA will hold shares of CNCR at aggregate net asset value ("NAV") (not the market value) of which will equal the aggregate NAV (not the market value) of the shares CHNA held by such shareholders as of the valuation time specified in CHNA's Prospectus (although such shareholders will receive cash for fractional shares).

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION

First Trust NASDAQ Global Auto Index Fund

iShares U.S. Home Construction ETF

SPDR S&P Regional Banking ETF

Invesco DWA Energy Momentum ETF

These sector ETFs have won and lost the most in the first half of 2023.

Best & Worst Sector ETFs of First-Half 2023

Advisorshares Managed Bitcoin Strategy ETF

Fidelity Disruptors ETF

VanEck Vectors Muni Allocation ETF

Global X MSCI Nigeria ETF

Invesco PureBeta FTSE Developed ex-North America ETF

Invesco PureBeta FTSE Emerging Markets ETF

Invesco PureBeta US Aggregate Bond ETF

Invesco PureBeta MSCI USA Small Cap ETF

Invesco Balanced Multi-Asset Allocation ETF

Invesco Conservative Multi-Asset Allocation ETF

Invesco Growth Multi-Asset Allocation ETF

Invesco Moderately Conservative Multi-Asset Allocation ETF

First Trust Developed International Equity Select ETF

AdvisorShares Drone Tech ETF

PIMCO Ultra Short Government Active ETF

Global X 1-3 Month T-Bill ETF

Future Fund Long/short ETF

FT Cboe Vest US Equity Moderate Buffer Etf-June

iShares iBonds Dec 2033 Term Corporate ETF

iShares iBonds 2030 Term High Yield and Income ETF

iShares Copper and Metals Mining ETF

iShares Lithium Miners and Producers ETF

PIMCO Multi Sector Bond Active ETF

Clouty Tune Etf

UVA Dividend Value ETF

It was a busy week for ETF launches and closures. A total of 15 ETFs launched during the week shortened by the Juneteenth holiday, defying the typically slow launch count for weeks surrounding three-day weekends.

Last Week in ETFs: 15 Launches, Closures Continue Rapid Pace

Aberdeen Standard Physical Palladium Shares ETF 

iPath Series B Bloomberg Platinum Subindex Total Return ETN

GraniteShares Platinum Trust

Aberdeen Standard Physical Platinum Shares ETF

Invesco DWA Healthcare Momentum ETF

Simplify Propel Opportunities ETF

In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way with a 10% return.

ALPS' Biotech ETF SBIO Week's Top Performer

Global X Genomics & Biotechnology ETF

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

Global X Longevity Thematic ETF 

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Global X Telemedicine & Digital Health ETF

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

Nasdaq Pharm Shs Nasdaq Pharmaceuticals

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares Global Healthcare ETF

iShares U.S. Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Merck

Novo Nordisk

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P SmallCap Health Care ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

First Trust NASDAQ Clean Edge Green Energy Index Fund

Consumer Discretionary Select Sector SPDR Fund

SPDR S&P Retail ETF

SPDR S&P Internet ETF

Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.

5 Top-Ranked ETFs to Buy at Bargain Prices for 2023

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

5 ETFs Riding High on the Biotech Comeback

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

News for Loncar Cancer Immunotherapy ETF ETF (CNCR)